Psychedelic Stocks Gain on Trump Order, Oppenheimer Predicts Continued Growth for Investors

Imagine if a new rule made it easier for inventors to test and sell a life-changing gadget—suddenly, everyone would want to know which companies might win big. That’s what just happened in the world of psychedelic drugs for mental health, and it matters for investors.

What’s Happening With Psychedelic Stocks?

President Trump signed an order that could speed up the process for companies making psychedelic drugs to treat mental illness. The order tells the Food and Drug Administration (FDA) to give special priority to certain drugs and asks the Drug Enforcement Agency (DEA) to help patients get access to these treatments while they’re still being studied.

This move is especially focused on helping veterans who are struggling with mental health issues. The government wants the Department of Veterans Affairs to help get more people involved in testing these new drugs. Plus, the order promises more federal funding, which could help companies run bigger studies and get their drugs to market faster.

Why Does This Matter for Investors?

For investors, this is like opening a shortcut for companies in the psychedelic sector. It could mean faster approval, fewer roadblocks, and more people able to use these treatments. That could boost the value of stocks in this industry.

• Bull case (pros):
  • Faster research and approval could mean companies make money sooner.
  • More federal funding reduces the cost and risk for these businesses.
  • Political support could help more people trust and use these treatments.
  • Some stocks, like Compass Pathways, already jumped by 42% in a single day after the news.
• Bear case (cons):
  • Even with faster approval, these drugs still need to prove they work and are safe.
  • There’s no guarantee insurance companies will pay for these treatments right away.
  • The sector is still new, so prices can swing wildly—big gains can be followed by big drops.

Key Players to Watch

Oppenheimer, a respected bank, thinks companies like AtaiBeckley, Compass Pathways, and Definium Therapeutics have special advantages. These stocks all got a boost after the news:

• Compass Pathways shot up 42%—its best day ever.
• AtaiBeckley jumped more than 21%.
• Definium Therapeutics rose over 2%.

Analysts polled by LSEG say all three stocks are buys, with average price targets suggesting big possible gains: AtaiBeckley and Compass could rise by 169% and 134%, while Definium might gain over 59% in the next year.

For context, a 2022 study published in JAMA Psychiatry found that psychedelic-assisted therapy helped reduce depression symptoms more than traditional treatments in some cases. This adds credibility to the excitement around these drugs.

Risks and Rewards: What Investors Should Know

• Upside: Big policy changes can create new opportunities for growth, especially in new areas like psychedelics for mental health.
• Downside: New sectors can be risky. Drug development takes time, and not all drugs succeed in trials.
• Historical context: In the past, when the FDA fast-tracked HIV/AIDS drugs in the 1980s, it led to faster approvals and big gains for early investors, but also came with risks and setbacks for some companies.

Investor Takeaway

• Consider adding a small position in leading psychedelic stocks, but keep your risk in check—this sector is still young and volatile.
• Watch for more government action and news about clinical trials; these can move stocks quickly.
• Diversify your portfolio. Don’t put all your money into one new sector, no matter how exciting it seems.
• Stay informed about research results and real-world use—credible studies and patient stories can drive investor confidence.
• Remember, fast gains can be tempting, but patience and caution are key when investing in new industries.

For the full original report, see CNBC